A drug of a revolutionary approach to treating cancer from birth causes rapid weight loss and improved metabolic function in monkeys have been established by researchers. Coming in the wake of several setbacks for the proposed diet drug, the early success of a peptide called "adipotide" by its creators can open a new front in the war against obesity, said several researchers.
The study, published Tuesday, describes studies that responded three species of primates for injections of the synthetic peptide by eating less, shed belly fat and changes in metabolic function is likely to hold in check for type 2 diabetes - a frequent consequence of over weight.
The trick behind the therapy: killing fat cells by robbing them of the blood supply that nourishes them.
This strategy, known as the inhibition of angiogenesis is the basis for more than 15 drugs for cancer of the brain, colon, lung and kidney to treat. The new study in the journal Science Translational Medicine reports, is the first, the strategy in primate testing for the treatment of obesity.
After four weeks of daily injections of adipotide and a four-week follow-up without treatment - lost 10 obese female rhesus monkeys, an average of 11% of body weight and 39% of fatty deposits - and without any forced changes in diet or exercise.
Much of this loss came three weeks after the drug was discontinued, in which the treated macaques continued to be lighter and slimmer.
Study co-author Dr. Wadih Arap, an oncologist at the MD Anderson Cancer Center in Houston, said of the approach with his wife, Renata Pasqualini, a cancer researcher at the center of pioneering work, satisfaction with the treated monkeys' weight loss and metabolic improvements. But he acknowledged that "we see a bit of a loss to explain," all effects in the two species of macaque and a small group of baboons that were tested.
He called the study a "proof of concept", and added that the study of the structure of the potential drug, "we are not done."
A key issue is security: the drug seemed to lead to dehydration, a moderate decrease of the Apes "phosphorus and potassium levels and kidney lesions in some small, these effects disappeared after the drug was discontinued, but it could be a cause for concern. be as the active ingredient in the phase of human clinical trials that begin in the coming months.
For the development of the drug further, MD Anderson has a Pasadena-based company, Arrowhead Research Corp. Arap and Pasqualini own shares of the company joined forces and founded the subsidiary Ablaris Therapeutics Inc., that the weight loss agents to bring to a destination potentially huge market.
Adipotide was developed only to the blood vessels that attach to the body's fat stores feed. Then she takes that to wither and die. Apparently much deprived of its blood supply, fat deposits respond by reducing fat cells.
Most notable of obesity researchers, the rapid release of fat cells in the bloodstream is apparently not in dangerous levels of fat by the body, where they expected that the blood vessels become inflamed, disrupt metabolism and promptly cause an increase in appetite could. Instead, the fat cells are burned as fuel.
What happens next is a matter of speculative knowledge. The monkeys received a daily intake of adipotide continue to be offered a wide range of foods to eat and they did not seem to suffer from nausea or discomfort. But they began to consume less than they had at the beginning. That said, Arap, was a surprise, since weight loss is usually preserve ramps, which provides the appetite as the body struggles to be fat.
Obesity researcher Randy Seeley of the University of Cincinnati College of Medicine, the Cincinnati diabetes and obesity directs the center, suggested that the body of the remaining fat depots messages to the brain's appetite centers, that they at full capacity and can not save possibly any more fat. Dictated the message: Eat less.
"What they have opened up a whole layer of biology, such as adipose tissue communicates with the brain and other organs of his status, and we had no idea until they came together," said Seeley, who was not involved in the study. He said he was until recently an ardent skeptic that this weight loss strategy would always work, but now the approach is "incredibly cool."
Others warned that much work needs to be done to better understand the mode of action adipotide and safety before a drug on the peptide-based ready for use in patients.
"This is exciting and very interesting work," Yihai Cao, a microbiologist at the Karolinska Institute in Sweden said that studies angiogenesis in tumors. But, he added, researchers must clearly show that adipotide is to reduce blood vessels that nourish fat, no other blood vessels, such as appetite and metabolic changes and improvements are related in that sense.
Cao also stressed that the gap between apes and humans, "a big leap."
"Whether to achieve this, the clinic remains to be seen," he said.
Have Arrowhead Research Corp. is expected in talks with the Food and Drug Administration and therefore, research studies on people running in a few months, said Chris Anzalone, the company's CEO. One of the first groups of patients should be tested in obese men with prostate cancer, more than twice as frequently as slimmer men will die of the disease, said Anzalone.
Meanwhile Ablaris Therapeutics is to change the address side effects and create a formulation that could be injected less frequently than daily could work.
Anzalone said that the drug probably was a short term solution to weight loss and metabolic risk that patients will win the difficult task of maintaining their health with diet and exercise afterwards.
"We'll see how this works in humans," said Anzalone. "My feeling is, this never intended for long-term use. Sometime after the drug, we believe that changes in lifestyle will have to take."
